Janus Henderson Group
TPST icon

Janus Henderson Group’s Tempest Therapeutics TPST Stock Holding History

Janus Henderson Group’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-11
Closed -$45K – 1339
2017
Q3 		$45K Hold
11
– – ﹤0.01% 1284
2017
Q2 		$49K Buy
+11
New +$46.5K ﹤0.01% 1306

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group's TPST Position: Q4 2017 in Review

Janus Henderson Group sold out of Tempest Therapeutics (TPST) in Q4 2017, closing a stake of 11 shares — an estimated $45K sold.

Janus Henderson Group first reported a position in TPST in Q2 2017 and held it in 2 quarters. The position peaked at $49K in Q2 2017. 50 funds tracked by Wall St. Rank hold TPST as of Q4 2017.

  • Janus Henderson Group reported no remaining Tempest Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Janus Henderson Group sold 11 Tempest Therapeutics shares in Q4 2017, an estimated $45K.
  • Janus Henderson Group first reported a position in Tempest Therapeutics in Q2 2017 and held it in 2 quarters.
  • Janus Henderson Group's Tempest Therapeutics position peaked at $49K in Q2 2017.
  • 50 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2017.

Based on Janus Henderson Group's 13F filing for Q4 2017, filed 9 Feb 2018.